National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 371-375

  Xue, Cong ^a   Hu, Zhihuang ^a   Jiang, Wei ^b   Zhao, Yuanyuan ^a   Xu, Fei ^a   Huang, Yan ^a   Zhao, Hongyun ^a   Wu, Jingxun ^c   Zhang, Yang ^a   Zhao, Liping ^a   Zhang, Jing ^a   Chen, Likun ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Chemotherapy; Chinese population; Epidermal growth factor receptor; Non small cell lung cancer; Practice pattern; Survey

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; PEMETREXED;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHINA; CLINICAL ARTICLE; CLINICAL PRACTICE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SALVAGE THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84863775476     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.04.014     Document Type: Article

References (15)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Globocan. International agency for research of cancer. 2008. http://globocan.iarc.fr/.
3. Doll R., Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Brit Med J 1976, 2:1525-1536.
4. Wald N.J., Nanchahal K., Thompson S.G., Cuckle H.S. Does breathing other people's tobacco smoke cause lung cancer?. Br Med J (Clin Res Ed) 1986, 293:1217-1222.
5. Weinstein M.C., Skinner J.A. Comparative effectiveness and health care spending-implications for reform. N Engl J Med 2010, 362:460-465.
6. National Comprehensive Cancer Network-Asia. Non-small cell lung cancer: treatment guidelines for patients. Version 1. http://www.nccn-asia.org/cn/.
7. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
8. D'Addario G., Fruh M., Reck M., Baumann P., Klepetko W., Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v116-v119.
9. National Comprehensive Cancer Network. Lung cancer: treatment guidelines for patients. Version 1. http://www.nccn.org/.
10. Potosky A.L., Saxman S., Wallace R.B., Lynch C.F. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol 2004, 22:3261-3268.
11. Gridelli C., Rossi A., de Marinis F. Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: a survey of the Italian Association of Thoracic Oncology (AIOT). Lung Cancer 2010, 67:339-342.
12. Ramsey S.D., Howlader N., Etienne R.D., Donator B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004, 22:4971-4978.
13. Gridelli C., Arizona A., Barn S., Chino L., Capriole A., Piazza E., et al. Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study. Lung Cancer 2011, 74:462-468.
14. Chen L.K., Xu G.C., Guan Z.Z., Hang Y., Yang Q.Y. Nadaplatin or cisplatin combined with paclitaxol in treatment for non-small cell lung cancer: a randomized controlled study. Zhonghua Zhong Liu Za Zhi 2007, 29:437-440.
15. Li M., Huang H., Tan J., Lin D. A randomized clinical trial on taxol plus oxaliplatin versus taxol plus cisplatin as first-line treatment in advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2006, 9:452-454.